Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03409588 · ClinicalTrials.gov registry record · Phase 2

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

A Phase 2 study, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target

NCT03409588 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03409588, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target

Study Summary

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

Interventions

  • DRUG Adempas

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2018-06-13
Est. Completion 2026-01-26
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT03409588

The ClinicalTrials.gov registry entry for NCT03409588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Adempas is the first listed.

NCT03409588 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03409588 about?

NCT03409588 is a clinical study titled "Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty". This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

What is the current status of trial NCT03409588?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-06-13. Estimated completion is 2026-01-26.

What interventions are being tested in trial NCT03409588?

The interventions under investigation include: Adempas (DRUG).

Who is sponsoring clinical trial NCT03409588?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.